The Clinically Important Difference on the Unified Parkinson's Disease Rating Scale

被引:445
作者
Shulman, Lisa M. [1 ]
Gruber-Baldini, Ann L. [2 ]
Anderson, Karen E. [1 ,3 ]
Fishman, Paul S. [1 ]
Reich, Stephen G. [1 ]
Weiner, William J. [1 ]
机构
[1] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA
[3] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA
关键词
QUALITY-OF-LIFE; MINIMALLY IMPORTANT DIFFERENCES; HEALTH-STATUS; DOUBLE-BLIND; MEANINGFUL DIFFERENCE; BROMOCRIPTINE; ROPINIROLE; RESPONSIVENESS; MONOTHERAPY; PRAMIPEXOLE;
D O I
10.1001/archneurol.2009.295
中图分类号
R74 [神经病学与精神病学];
学科分类号
100204 [神经病学];
摘要
Objective: To determine the estimates of minimal, moderate, and large clinically important differences (CIDs) for the Unified Parkinson's Disease Rating Scale (UPDRS). Design: Cross-sectional analysis of the CIDs for UPDRS total and motor scores was performed on patients with Parkinson disease (PD) using distribution-and anchor-based approaches based on the following 3 external standards: disability (10% on the Schwab and England Activities of Daily Living Scale), disease stage (1 stage on the Hoehn and Yahr Scale), and quality of life (1 SD on the 12-Item Short Form Health Survey). Setting: University of Maryland Parkinson Disease and Movement Disorders Center, Patients: Six hundred fifty-three patients with PD. Results: A minimal CID was 2.3 to 2.7 points on the UPDRS motor score and 4.1 to 4.5 on the UPDRS total score. Amoderate CID was 4.5 to 6.7 points on the UPDRS motor score and 8.5 to 10.3 on the UPDRS total score. A large CID was 10.7 to 10.8 points on the UPDRS motor score and 16.4 to 17.8 on the UPDRS total score. Conclusions: Concordance among multiple approaches of analysis based on subjective and objective data show that reasonable estimates for the CID on the UPDRS motor score are 2.5 points for minimal, 5.2 for moderate, and 10.8 for large CIDs. Estimates for the UPDRS total score are 4.3 points for minimal, 9.1 for moderate, and 17.1 for large CIDs. These estimates will assist in determining clinically meaningful changes in PD progression and response to therapeutic interventions.
引用
收藏
页码:64 / 70
页数:7
相关论文
共 46 条
[1]
Sufficiently important difference: Expanding the framework of clinical significance [J].
Barrett, B ;
Brown, D ;
Mundt, M ;
Brown, R .
MEDICAL DECISION MAKING, 2005, 25 (03) :250-261
[2]
Interpreting score differences in the SF-36 Vitality scale: using clinical conditions and functional outcomes to define the minimally important difference [J].
Bjorner, Jakob B. ;
Wallenstein, Gene V. ;
Martin, Marie C. ;
Lin, Peggy ;
Blaisdell-Gross, Bonnie ;
Piech, Catherine Tak ;
Mody, Samir H. .
CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (04) :731-739
[3]
A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa [J].
Brunt, ER ;
Brooks, DJ ;
Korczyn, AD ;
Montastruc, JL ;
Stocchi, F .
JOURNAL OF NEURAL TRANSMISSION, 2002, 109 (04) :489-502
[4]
Caplan Louis R, 2007, Rev Neurol Dis, V4, P75
[5]
Cohen J., 1988, Statistical power analysis for the behavioral sciences, VSecond
[6]
Understanding the minimum clinically important difference: a review of concepts and methods [J].
Copay, Anne G. ;
Subach, Brian R. ;
Glassman, Steven D. ;
Polly, David W., Jr. ;
Schuler, Thomas C. .
SPINE JOURNAL, 2007, 7 (05) :541-546
[7]
Fahn S, 2004, NEW ENGL J MED, V351, P2498
[8]
Fahn S., 1987, RECENT DEV PARKINSON, V2
[9]
MINI-MENTAL STATE - PRACTICAL METHOD FOR GRADING COGNITIVE STATE OF PATIENTS FOR CLINICIAN [J].
FOLSTEIN, MF ;
FOLSTEIN, SE ;
MCHUGH, PR .
JOURNAL OF PSYCHIATRIC RESEARCH, 1975, 12 (03) :189-198
[10]
*FOOD DRUG ADM CTR, 2006, GUID IND PAT REP OUT